Accustem Sciences Inc. financial data

Symbol
ACUT on OTC
Industry
Pharmaceutical Preparations
Location
5 Penn Plaza, 19 Th Floor, #1954, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
AccuStem Sciences Ltd (to 7/1/2021)
Latest financial report
10-Q - Q3 2024 - Nov 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.72 % -87.8%
Debt-to-equity -104 % +28%
Return On Equity 51 % -80.4%
Return On Assets -1.29K % -120%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11.3M shares
Common Stock, Shares, Outstanding 11.3M shares 0%
Entity Public Float 16M USD +416%
Common Stock, Value, Issued 11.3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 11.3M shares 0%
Weighted Average Number of Shares Outstanding, Diluted 11.3M shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 186K USD +1.44%
General and Administrative Expense 1.19M USD -54.1%
Operating Income (Loss) -1.38M USD +50.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.38M USD +50.5%
Net Income (Loss) Attributable to Parent -1.38M USD +50.5%
Earnings Per Share, Basic -0.13 USD/shares +43.5%
Earnings Per Share, Diluted -0.13 USD/shares +40%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current 29.6K USD
Assets, Current 102K USD -59.4%
Property, Plant and Equipment, Net 1.33K USD -73.3%
Assets 104K USD -59.7%
Accounts Payable, Current 790K USD +82.8%
Accrued Liabilities, Current 164K USD -64.8%
Liabilities, Current 3.3M USD +53.9%
Liabilities 3.3M USD +53.9%
Retained Earnings (Accumulated Deficit) -7.65M USD -22%
Stockholders' Equity Attributable to Parent -3.19M USD -69.4%
Liabilities and Equity 104K USD -59.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -237K USD +46.8%
Net Cash Provided by (Used in) Financing Activities 225K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 11.3M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -12.1K USD +97.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 697 USD -0.71%
Deferred Tax Assets, Valuation Allowance 1.36M USD +55.2%
Depreciation 3.63K USD +0.03%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.79M USD -157%
Property, Plant and Equipment, Gross 11K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 1.23M USD +68.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 4.45M USD +1.62%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.36M USD +55.2%
Share-based Payment Arrangement, Expense 169K USD +497%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%